cyrilzakka/clinical-trials huggingface dataset:
Graston vs Manual Myofascial Release Technique in Piriformis Syndrome.

The objective of our study is to compare the effects of Graston and manual myofascial release technique on pain, muscle length and functional status in patients with Piriformis syndrome.

In 2019, a study was conducted to conclude the effectiveness of Passive stretching v/s Myofascial release in improving Piriformis flexibility in females. They reported that myofascial release was more valuable than passive stretching exercises in enhancing piriformis flexibility in patients with piriformis tightness.

According to another study in 2018, after a single treatment, compressive myofascial release showed more improvement in ankle dorsiflexion than Graston technique, in participants with decrease dorsiflexion range.

In 2016, a study reported the effects of the Graston technique and general exercise in patients with chronic low back pain. Graston group showed greater improvement in pain and range of motion in patients with chronic low back pain.

According to a study conducted in 2014, self-myofascial release was more effective than Graston technique in improving knee joint flexibility, hamstring, and quadriceps strength.

In 2011, a study evaluated the effectiveness of deep soft tissue mobilization techniques and stretching exercises in piriformis syndrome and found that the deep soft tissue mobilization techniques along with stretching exercises significantly improved the piriformis syndrome.

Eligibility Criteria:
Inclusion Criteria:•

* Pain more than 1 month.
* Piriformis syndrome diagnosed through screening test (FAIR test, Beatty test, Freiberg test, Sign of Pace)

Exclusion Criteria:

* Leg pain due to causes other than piriformis syndrome.
* Congenital spinal deformity.
* History of fracture.
* History of back or hip surgery.
* Any systemic illness like metastatic or infective disorders.
Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

The purpose of this study is to investigating the absorption, metabolism and excretion of radio labelled single doses of idalopirdine in healthy men.


Eligibility Criteria:
Inclusion Criteria:

* Healthy men
* aged between 40-60 years (inclusive)
* BMI in the range 19 and 30 kg/m2 (minimum weight 60 kg)

Exclusion Criteria:

* The subject has previously been dosed with idalopirdine.

Other protocol defined inclusion and exclusion criteria do apply
Weaning From Mechanical Ventilation in Patients With Acute Brain Injury

Acute brain injury (ABI) patients frequently necessate intubation and invasive mechanical ventilation (IMV). While some ABI patients are capable of breathing spontaneously, which is one of the main criteria of extubation and weaning. However, the rate of extubation failure was significantly higher in ABI patients compared with non-neurological critical care patients. In patients who have failed one or several trials of extubation, tracheostomy is recommend according to the latest ESICM consensus. Tracheostomy can enhance comfort, improve pulmonary hygiene and decrease sedation requirement, which could facilitate the liberation from ventilator.

Numerous studies have explored the causes of weaning failure and provide various predictive models in guiding extubation and tracheostomy. Yet, due to limitations of such as small sample size or a lack of external validation, there is paucity of practical weaning algorithm tailored for ABI patients. The liberation from IMV in ABI patients still remains challenging with poor level of evidence in current guidelines or expert consensus.

We aim to describe the weaning outcomes in ABI patients, and further investigate the potential predictors of weaning success in ABI patients.


Eligibility Criteria:
Inclusion Criteria:

* acute brain injury
* age \>=18 years
* invasive mechanical ventilation for at least 24 hours

Exclusion Criteria:

* tracheostomized before ICU admission
* pregnant or lactation
* with cervical spinal cord injury
* decision to receive palliative care within 24 hours of ICU admission
The Impact of Family CTI on Homeless Children

The purpose of this study is to examine how services and housing provided for homeless families affect the mental health and behavior of homeless children over time.

This study is a supplement to a parent study which concentrates on the outcomes of homeless mothers who are provided with services and housing. This study will focus on the effects of housing and services on children, who may be the major beneficiaries of such assistance.

Participants are randomly assigned to either receive services and permanent housing or to remain in a homeless shelter without additional assistance. Children and their parents are interviewed separately 3, 9, and 15 months after study entry. The teachers of participating children are surveyed twice during the study.

Eligibility Criteria:
Inclusion Criteria:

* Enrollment in the parent study
* Homeless and living at a shelter with mother/maternal guardian at the time of study enrollment
Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo

The etiology of bone marrow edema (BME) is still uncertain. Several studies report therapeutic success with antiresorptive drugs.

This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME

Patients are assigned to receive either denosumab 60mg sc (once) or placebo or daily teriparatide sc for three months or placebo.

MRI examinations at baseline and after three months will be performed. Serum bone turnover markers will be evaluated as well as QoL questionnaires.

Eligibility Criteria:
Inclusion Criteria:

* MRI diagnosed bone marrow edema

Exclusion Criteria:

* any prior antiresorptive or osteoanabolic treatment
* any prior therapy with strontium ranelate
* Hyper-/hypocalcemia
* malignancies
* pregnancy
* and contraindication against denosumab or teriparatide
Impedance Pneumography Measurement During Acute Airway Obstruction and Recovery Phase in Young Children

The purpose of this study is to evaluate the association of signals recorded and analysed with Ventica® LFTS in infants and preschoolers during acute airway obstruction/asthma exacerbation and recovery thereof for changes in the IP-derived TBFV curves within and between nights.


Eligibility Criteria:
Inclusion Criteria:

* Age 1-7
* Diagnosis of acute airway obstruction or asthma exacerbation requiring inpatient treatment

Exclusion Criteria:

* Need for an ICU treatment
* Bronchiolitis
* Pneumonia (not including viral infections)
* Other cardiorespiratory or neurological chronic diseases or states that may significantly alter the overnight breathing pattern
* Implanted or external active medical devices
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)

An effective, widely available, and safe treatment that can decrease the duration, severity and fatality of COVID-19 is urgently needed. Also, in the most affected regions the pressure on health care systems including ventilator support capacity can be a limiting factor for survival. Initial studies including from our group indicate that administering convalescent plasma containing high titers of neutralizing antibodies to COVID-19 patients who are already relatively late during the disease course after hospital admission is not effective, which can be explained by high titers of autologous antibodies present in patients. Thus, the antiviral capacity of convalescent plasma is hypothesized to be best positioned early in the disease course and in patients at increased risk for a severe disease course. If effective, any treatment that decreases the need for hospital admission is very valuable but so far, no COVID-19 treatment has been shown to prevent clinical deterioration when given before patients are admitted to the hospital.

Primary objective:

To evaluate the efficacy, feasibility and safety following the administration of convalescent plasma (ConvP) as a therapy for outpatients diagnosed with COVID-19 at increased risk for an unfavourable clinical outcome and within 7 days after symptom onset.

Study design:

This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP).

Patient population:

Patients with polymerase chain reaction (PCR) confirmed COVID disease with less than 8 days of symptoms, age 70 or older or 50-69 years with at least 1 additional risk factor for severe COVID-19 are eligible.

Intervention:

300mL of convP with a minimum level of neutralizing antibodies.

A total of 690 patients will be included. Expected duration of accrual: 18-24 months Duration of follow up :Day 28 for the primary endpoint

Secondary (exploratory) objectives

* To evaluate the impact of 300mL convP on mortality
* To evaluate the impact of 300mL convP on hospital admission
* To evaluate the impact of 300mL convP on admission to ICU
* To evaluate the impact of 300mL convP on duration of symptoms
* To evaluate the impact of 300mL convP in relation to the age and clinical frailty of the patient

Eligibility Criteria:
Inclusion Criteria:

* RT-PCR-confirmed COVID-19.
* Symptomatic (e.g but not limited to fatigue, fever, cough, dyspnoea, loss of taste or smell, diarrhea, falls or confusion)
* 70 years or older OR 50-69 years and 1 or more of the risk factors described in the protocol

Exclusion Criteria:

* Life expectancy \<28 days in the opinion of the treating physician
* Patient or legal representative is unable to provide written informed consent
* Symptomatic for 8 days or more
* Being admitted to the hospital at the informed consent procedure
* Known previous history of transfusion-related acute lung injury
* Known Immunoglobulin A (IgA) deficiency
PARKINSON BRASIL - Database on Motor and Non-Motor Aspects of Parkinson's Disease in Brazil

This is an observational, cross-sectional study with a control group, with the general objective of developing and evaluating a national database, unprecedented in Brazil, containing clinical, epidemiological, motor, and non-motor aspects of Parkinson's disease (PD). The database will be open and accessible to national and international researchers in order to contribute to the advancement of research related to PD. The aim is to collect data, in a paired way, from a control group and an experimental group. Data collection will include the application of questionnaires, the execution of motor activities, and clinical scales. Information that can identify the participants will be removed from the database for later storage in a repository. Quantitative, qualitative, and descriptive variables from the database will be estimated in order to characterise and contrast the groups studied. The results of this study will contribute to a better characterization of the staging of PD as a function of the epidemiological, motor, and non-motor aspects evaluated, as well as to the development of technologies and methods that can be applied in clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Experimental group: (i) present a neurological diagnosis of Parkinson's disease; (ii) be classified between stages I to IV of the Hoehn \& Yahr Scale; (iii) have central visual acuity equal to or greater than 20/40 (equivalent to 0.50) in each eye or equal to or greater than 20/30 (equivalent to 0.66) in one eye according to the Snellen scale.
* Control group: (i) not having a neurological diagnosis of Parkinson's disease or other neurological disease that resembles PD; (ii) have central visual acuity equal to or greater than 20/40 (equivalent to 0.50) in each eye or equal to or greater than 20/30 (equivalent to 0.66) in one eye according to the Snellen scale.

Exclusion Criteria:

For both groups, individuals who have other neurological or musculoskeletal diseases that interfere with the execution of the tests will be excluded.
Sms-guided Training After Acute Stroke or Transient Ischemic Attack - a Randomized Controlled Trial

Eighty community-living individuals in Uppsala municipality will be included. Intervention: Outdoor walking exercise program and one strength exercise. Methods: Clinical assessments, questionnaires and medical records. Assessment of motor function, cognition, level of physical activity, food intake and perceived stress are performed at screening as baseline measurements. Walking capacity, mobility, handgrip strength, body composition and cardiovascular risk markers will be assessed at baseline and after 12 week of training. At one year after training health-related quality of life, another cardiovascular incidence and mortality will be documented.

Eighty community-living individuals in Uppsala municipality will be included in a randomized controlled trial with two arms.

Intervention: Participants will perform an outdoor walking exercise program together with one strength exercise for 12 weeks. The intensity and frequency of the training will progressively increase. Participants are supposed to walk and perform strength training 5-7 days/week.

Methods: Clinical assessments, questionnaires and medical records used for documentation of age, sex, comorbidity, blood pressure, medications and previous education.

Assessment of motor function, cognition, level of physical activity, food intake and perceived stress are performed at screening as baseline measurements. Walking capacity (primary outcome measure), mobility, handgrip strength, body composition and cardiovascular risk markers will be assessed at baseline and after 12 week of training. At one year after training health-related quality of life, another cardiovascular incidence and mortality will be evaluated.

Power analysis is performed. The investigators will analyze the data using an intention-to -treat analysis. Participants should have participated in at least 50% of the training sessions

Eligibility Criteria:
Inclusion Criteria:

1. Verified ischemic cerebral infarction or intracerebral hemorrhage.
2. Sufficient walking capacity and motor function
3. Able to communicate in Swedish
4. Signed consent

Exclusion Criteria:

One or more of the following:

1. Subarachnoid bleeding
2. Insufficient cognition and impaired ability to understand instructions
3. Medical problems that make it unsuitable to participate
4. Pacemaker (body composition measurements)
Relationship Between Cervical Pain and Temporomandibular Dysfunction Craniovertebral Angle, Jaw Functional Limitation and Cervical Mobility

The aim of this study is to examine temporomandibular dysfunctions, jaw functional limitation, cervical mobility and craniovertebral angles and possible relations between individuals with cervical pain and individuals without cervical pain and to compare the this four variables between the two groups.

This study was conducted with 129 individuals (mean age 34.08:years, M/F=52/77) to determine the possible relationships between Cervical Pain and Temporomandibular Dysfunction, Craniovertebral Angle, Jaw Functional Limitation and Cervical Mobility. Pati,ents were assessed with Neck Pain and Disability Questionnaire , Fonseka Anamnestic Index , goniometric measurements, ,Cervical Mobility Measurement. JFSL-20 questionnaire and Craniovertebral Angle measurement was made by photographic method.

Eligibility Criteria:
Inclusion Criteria:

Neck pain disability score below 15 Not having painting problem for TME Being in the age range of 18-50 Volunteering to participate in the study

Exclusion Criteria:

* he presence of any orthopedic and / or neurological problem that may prevent evaluations.

Being diagnosed with any psychiatric disorder Situations that will prevent evaluation or communication

* Illiterate individuals
* Head, neck and maxillofacial surgery operation history
* Conditions in systemic pathological conditions such as malignant condition, fracture and rheumatoid arthritis
Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD

This study will evaluate the safety and efficacy of Jianfei Kangfu Cao in the treatment of primary Sjogren's syndrome associated interstitial lung disease.

This study will be a randomized, double-blind, positive control clinical trial with a course of 24 weeks.

1. Random scheme:the DAS for Interactive Web Response System(IWRS) will be used to calculate and distribute random numbers and dispensing drugs.
2. Blind method ：The test process will be in a double-blind state.
3. Control drug: The lung rehabilitation training will be used as control in this trial.

Eligibility Criteria:
Inclusion Criteria:

1. According to the 2012 ACR classification of primary Sjogren's syndrome .
2. CT confirmed interstitial lung disease;
3. DLCO≧40%;
4. Stable treatment for at least 12 weeks;
5. Patients with good compliance should sign informed consent before the tria.

Exclusion Criteria:

1. The patient is using or has used anti pulmonary fibrosis drugs;
2. Pulmonary infection, tumor and other connective tissue diseases;
3. Chronic obstructive pulmonary disease, bronchial asthma and tuberculosis;
4. Patients with severe hypertension, diabetes and heart, liver and renal failure;
5. Women with reproductive needs;
6. Idiopathic pulmonary interstitial disease;
7. The researcher thinks that it is not suitable to participate in this experiment;
8. Participants in other clinical trials.
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of children with hemophilia A. The study is open to pediatric patients in Canada who completed Baxter Study 060101.


Eligibility Criteria:
Inclusion Criteria:

* Subject must have participated and completed participation in Baxter's clinical study 060101
* Subject or parent/legally authorized representative has provided written informed consent

Exclusion Criteria:

* Subjects who have withdrawn from Baxter's Clinical Study 060101 prior to the termination of the study
Fatigue and Kinematics During Isometric Activity of the Upper Limbs in Young and Older Adults

The aim of this study is to understand the relationship between perceived effort and physiological and kinematic variables caused by isometric activity of the upper limbs, as well as its relationship with socio-demographic characteristics, level of activity and quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Healthy
* Minimum age of 18 years;

Exclusion Criteria:

* Unable to provide written consent
* History of heart, cardiovascular and / or respiratory disease,
* Known untreated hypertension, cardiomyopathy, or exercise intolerance
* Presence of cognitive or neurological disorders
* Neuromuscular or orthopaedic disorder that limits the movement of the upper limb to 90° flexion or the maintenance of that position
* BMI ≥ 40
Comparison of GAP-score With Schwab-score

The predictive value of two different score-systems with regard to failure rate following long extent spinal fusion is subject of evaluation.

The multilevel spinal fusion is associated with high rate of failure. This results from insufficient adaptation of the fused spine to the proper individual spinal alignment. In the recent years, comprehensive understanding of spinal alignment and definition of several parameters contributed to develop score systems to evaluate the alignment of the multilevel spinal fusion and to predict failure. In the following study the results of multilevel spinal fusion were evaluated retrospectively according to two scoring systems: GAP-score und Schwab-score. The predictive value of each score system is analyzed by the correlation of the failure rate with its corresponding score value.

Eligibility Criteria:
Inclusion Criteria:

* 3 and more fusion levels

Exclusion Criteria:

* Neuromuscular disease
The Evaluation and Management of Patients With Acute Chest Pain in China

The purpose of this study is to describe the characteristics, evaluation, management and outcomes of acute chest pain, and to provide opportunities for future initiatives to improve the emergency care for patients experiencing acute chest pain in China.


Eligibility Criteria:
Inclusion Criteria:

* Acute chest pain(pain in the area inferior to the clavicle, superior to the rib arch, and anterior to the bilateral posterior axillary line）;
* Possible Acute Coronary Syndrome;
* Symptoms occurring within last 24 hours;
* Informed consent from patient or next of kin.

Exclusion Criteria:

* Arrhythmia or heart failure not cause by myocardial ischemia;
* Confirmed lung disease without chest pain;
* No onset of symptoms within last 24 hours;
* No written consensus.
Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

The overall goal of this study is to examine the effect of a single dose of TENS on mucositis pain and function secondary to head and neck radiation therapies. Oral mucositis is an extremely debilitating, unpreventable condition (inflammation, ulcers, bleeding in the mouth, nose, and throat) that causes significant pain, functional impairment, and diminished quality of life. Head and neck cancers pose specific challenges to effective pain management and past studies suggest the use of effective non-pharmacologic strategies such as TENS may be particularly beneficial for avoiding sources of acute and chronic pain, thereby improving quality of life. The investigators hypothesize that a single dose of TENS will decrease pain and improve function and quality of life in head and neck cancer patients. This project is particularly innovative because it is the first known study to examine the efficacy of TENS, an established safe, inexpensive and easy-to-use non-pharmacologic pain management intervention, for treating acute oral mucositis pain. The investigators research translates bench (animal model) science to human subjects using an interdisciplinary approach to pain management. Establishing whether TENS is effective for reducing mucositis pain is a critical first step toward establishing an effective, non-pharmacologic pain relief intervention for mucositis.


Eligibility Criteria:
Inclusion Criteria:

* Head and Neck Cancer Diagnosis
* Oral mucositis diagnosis

Exclusion Criteria:

* TENS use ≤ 5 years
* Pacemaker
* Pregnancy
Is There an Association Between Chronic Pancreatitis and Pulmonary Function

To evaluate pulmonary function in chronic pancreatitis compared with healthy volunteers and patients with cirrhosis.


Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic pancreatitis or cirrhosis
* Healthy controls

Exclusion Criteria:

* Lack of informed consent
* Known chronic lung disease